Want to join the conversation?
Global pharmaceutical company $MYL said it launched its Almotriptan Tablets USP, 6.25 mg & 12.5 mg, the generic version of migraine drug Axert, in the U.S. $MYL said it had received final FDA approval for its abbreviated new drug application for the product that is used for the acute treatment of migraine attacks in adults.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.